Skip to main content
×
Home
    • Aa
    • Aa

Effectiveness of trivalent and monovalent influenza vaccines against laboratory-confirmed influenza infection in persons with medically attended influenza-like illness in Bavaria, Germany, 2010/2011 season

  • H. ENGLUND (a1) (a2), H. CAMPE (a1) and W. HAUTMANN (a1)
Abstract
SUMMARY

We estimated the vaccine effectiveness (VE) of trivalent and monovalent influenza vaccines, respectively, against laboratory-confirmed influenza infections in patients with influenza-like illness who visited physicians participating in the Bayern Influenza Sentinel in Bavaria, Germany during 2010/2011. Swab specimens were analysed for influenza A(H1N1)pdm09, A(H3) and B by PCR. VE was estimated using the test-negative case-control study design and logistic regression. In total, 1866 patients (790 cases, 1076 controls) were included. The VE of trivalent vaccines administered in season 2010/2011 against laboratory-confirmed infection with any influenza virus, adjusted for age group, sex, chronic illness and week of arrival of the specimen, was 67·8% [95% confidence interval (CI) 39·2–82·9)]. The adjusted VE of monovalent influenza vaccines administered in season 2009/2010 against laboratory-confirmed influenza A(H1N1)pdm09 infection in 2010/2011 was 38·6% (95% CI −70·0 to 77·8). This is the first VE study conducted in Bavaria. We concluded that the trivalent influenza vaccines were effective in our study population.

Copyright
Corresponding author
*Author for correspondence: Ms H. Englund, Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, Veterinärstraße 2, 85762 Oberschleißheim, Germany. (Email: helene.englund@smi.se)
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

7. EW Orenstein , Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. International Journal of Epidemiology 2007; 36: 623631.

10. JK Yin , Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 2012; 30: 32093222.

15. M Valenciano , Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks. Vaccine 2010; 28: 73817388.

16. S Jiménez-Jorge , Effectiveness of the 2010–11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine 2012; 30: 35953602.

19. PR Blank , Trends in influenza vaccination coverage rates in Germany over six seasons from 2001/02 to 2006/07. Medizinische Klinik (Munich) 2008; 103: 761768.

21. MM Böhmer , Seasonal influenza vaccine uptake in Germany 2007/2008 and 2008/2009: results from a national health update survey. Vaccine 2011; 29: 44924498.

23. JM Langley , Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. Pediatric Infectious Disease Journal 2012; 31: 848858.

24. C Nassim , Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to <9 years of age. Pediatric Infectious Disease Journal 2012; 31: e59e65.

25. A Saitoh , Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized trial in Japanese children aged 6 months to 17 years. Human Vaccines & Immunotherapeutics 2012; 8: 749758.

26. WT Walker , H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study. Clinical Infectious Diseases 2012; 54: 661669.

27. M Ferguson , Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. Journal of Infectious Diseases 2012; 205: 733744.

28. H Ikematsu , Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults. Human Vaccines & Immunotherapeutics 2012; 8: 260266.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Epidemiology & Infection
  • ISSN: 0950-2688
  • EISSN: 1469-4409
  • URL: /core/journals/epidemiology-and-infection
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Full text views

Total number of HTML views: 1
Total number of PDF views: 13 *
Loading metrics...

Abstract views

Total abstract views: 75 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 29th May 2017. This data will be updated every 24 hours.